key: cord-0758540-wfy88u7p
authors: Leonardi, Andrea; Rosani, Umberto; Cavarzeran, Fabiano; Daull, Philippe; Garrigue, Jean‐Sebastien; Paola, Brun
title: Antiviral response in vernal keratoconjunctivitis may be protective against COVID‐19
date: 2021-08-21
journal: Allergy
DOI: 10.1111/all.15048
sha: f9611d0c7250523b12c536b171e358f9e1c3ebdf
doc_id: 758540
cord_uid: wfy88u7p

nan

To the Editor, Vernal keratoconjunctivitis (VKC) is a severe type 2 ocular eosinophilic inflammation with a proven IgE sensitization in about 50% of patients. Many Th2-type and proinflammatory cytokines have been found to be locally overexpressed in VKC patients, recalling a sort of local cytokine storm. Conjunctivitis is a common, self-limiting manifestation of COVID-19 with an incidence of 11% in affected patients, 1 but can be the first or the unique manifestation of SARS-CoV-2 infection. As a referral center for the diagnosis and treatment of VKC, so far, we observed only two VKC patient affected by COVID-19 without any ocular symptoms or consequences. The prevalence of VKC is estimated in our area 4/10.000 under 15 years of age. 2 Knowing that the prevalence of COVID-19 in pediatric population (0-14) in Padova great area is 6.4%, we calculated that the odds ratio (OR) for VKC to be associated with COVID-19 is OR = 0.88 (95% CI, 0.66-1.16), therefore, with a tendency for VKC to be protective. It has been suggested that a Th2-skewed immunity may be protective against severe COVID-19 disease. 3 For this reason, we investigated the conjunctival expression of genes related to the local defense immunity to virus that may play a relevant role in the response to SARS-CoV-2.

Conjunctival samples were collected from 15 VKC patients and 5 healthy age-matched control subjects (CTRL) using the Eyeprim TM device (OPIA Technologies SAS). Samples were immediately treated and stored at −80℃ for subsequent RNA isolation and Affymetrix assay (see Appendix S1). Over the 21,448 tested expression probes, using the Gene Ontology Biological Process (GOBP) term "defense response to virus," 237 genes were selected ( Figure S1 ). In addition, using bibliographic elements, we selected genes with SARS-CoV-2 receptor function and antiviral activity. The receptor angiotensinconverting enzyme 2 (ACE2), cellular transmembrane serine pro- (Table 1 and Figure 1 ). Even though several members of the interferon regulatory and inducible proteins (Table 1) were overexpressed in VKC, genes encoding for interferons were not. Notably, interferon receptors IFNAR1 (FC = 1.88; p = 0.003),

The meaning of the upregulation of all these antiviral genes in VKC is not clear. It has been shown that ACE2 is overexpressed in diseased conjunctiva compared to normal tissues and that conjunctival inflammation can enhance its expression. 4 Our results show that this is not the case for allergic inflammation. It has been suggested that type 2 immune response can provide certain protective effects against COVID-19 since asthma patients do not have increased susceptibility or severity of SARS-CoV-2 infection than others. 5 Although the presence of SARS-CoV-2 in tears has rarely been detected in infected individuals, the conjunctiva is a potential gateway for the SARS-CoV-2 and conjunctivitis may be a sign of COVID-19 prior to or after the onset of respiratory symptoms. In our study, we suggest that the overexpression of multiple antiviral factors in severe allergic inflammation and the low ACE2 expression in the conjunctiva might explain to the low prevalence of COVID-19 in VKC. In addition, it has been shown that having eosinophilia and a Th2 phenotype (which are typical of VKC) may be an important predictive factor for reduced COVID-19 morbidity and mortality in asthma. 6 We cannot translate this statement for VKC patients, but we suggest that having a local persistent allergic inflammation might be protective for ocular viral infections.

This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. 

Additional supporting information may be found online in the Supporting Information section.

Histogram showing the levels of expression of selected genes in VKC patients and control subjects (CTRL). The selection includes genes involved in the antiviral response. VKC, vernal keratoconjunctivitis

Ocular manifestations of COVID-19: a systematic review and meta-analysis

Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study

Is asthma protective against COVID-19?

Co-expression of SARS-CoV-2 entry genes in the superficial adult human conjunctival, limbal and corneal epithelium suggests an additional route of entry via the ocular surface

The evidence is in that asthma is not associated with severe coronavirus disease 2019

Eosinophilia in asthma patients is protective against Severe COVID-19 illness